News

Pfizer licenses 3SBio cancer drug for $1.25B upfront
Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug ...
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Key Takeaways Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe.Chinese firm 3SBio is developing a drug that is in trials to treat ...